These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 31682514)

  • 41. Combination measles, mumps, rubella and varicella vaccine.
    Arbeter AM; Baker L; Starr SE; Levine BL; Books E; Plotkin SA
    Pediatrics; 1986 Oct; 78(4 Pt 2):742-7. PubMed ID: 3763291
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Clinico-immunologic evaluation of a trivalent vaccine against measles, rubella and mumps].
    Schettini F; Manzionna MM; De Mattia D; Amendola F; Di Bitonto G
    Minerva Pediatr; 1989 Mar; 41(3):117-22. PubMed ID: 2747598
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Measles, mumps and rubella immunisation in children at risk of infection with human immunodeficiency virus.
    Molyneaux PJ; Mok JY; Burns SM; Yap PL
    J Infect; 1993 Nov; 27(3):251-3. PubMed ID: 8308316
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Economic analysis of measles elimination program in the Republic of Korea, 2001: a cost benefit analysis study.
    Bae GR; Choe YJ; Go UY; Kim YI; Lee JK
    Vaccine; 2013 May; 31(24):2661-6. PubMed ID: 23602654
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Administration of measles, mumps, and rubella virus vaccine (live) to egg-allergic children.
    Lavi S; Zimmerman B; Koren G; Gold R
    JAMA; 1990 Jan; 263(2):269-71. PubMed ID: 2294292
    [No Abstract]   [Full Text] [Related]  

  • 46. [Field trial with a new human diploid cell vaccine (HDCV) against measles, mumps and rubella].
    Just M; Berger R; Glück R; Wegmann A
    Schweiz Med Wochenschr; 1985 Nov; 115(48):1727-30. PubMed ID: 4081704
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Mass vaccination programme aimed at eradicating measles, mumps and rubella in Sweden: vaccination of schoolchildren.
    Böttiger M; Christenson B; Taranger J; Bergman M
    Vaccine; 1985 Jun; 3(2):113-6. PubMed ID: 4036269
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Morbidity, vaccine coverage and immunity against measles, mumps and rubella in a Gallician population from 2 to 5 years old].
    Vázquez Fernández E; López Rois F; Vázquez Carrete JA; Gómez Tato B; Alvarez Ares M
    An Esp Pediatr; 1987 Jul; 27(1):27-31. PubMed ID: 3662251
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Children who miss immunisation: implications for eliminating measles.
    Evans MR
    BMJ; 1995 May; 310(6991):1367-8. PubMed ID: 7787540
    [No Abstract]   [Full Text] [Related]  

  • 50. Clinical evaluation of a new measles-mumps-rubella combined live virus vaccine in the Dominican Republic.
    Ehrenkranz NJ; Ventura AK; Medler EM; Jackson JE; Kenny MT
    Bull World Health Organ; 1975; 52(1):81-5. PubMed ID: 764997
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Age-stratified seroprevalence of measles, mumps and rubella (MMR) virus infections in Switzerland after the introduction of MMR mass vaccination.
    Matter L; Germann D; Bally F; Schopfer K
    Eur J Epidemiol; 1997 Jan; 13(1):61-6. PubMed ID: 9062781
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Measles, mumps, and rubella: prevention.
    Booy R; Sengupta N; Bedford H; Elliman D
    Clin Evid; 2006 Jun; (15):448-68. PubMed ID: 16973018
    [No Abstract]   [Full Text] [Related]  

  • 53. Measles-mumps vaccination in the FRG: an empirical analysis after 14 years of use. I. Efficacy and analysis of vaccine failures.
    Fescharek R; Quast U; Maass G; Merkle W; Schwarz S
    Vaccine; 1990 Aug; 8(4):333-6. PubMed ID: 2396472
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pancreatitis caused by measles, mumps, and rubella vaccine.
    Adler JB; Mazzotta SA; Barkin JS
    Pancreas; 1991 Jul; 6(4):489-90. PubMed ID: 1876605
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Issues related to rubella, measles and epidemic parotiditis in the Russian Federation].
    Zverev VV; Iuminova NV
    Vopr Virusol; 2004; 49(3):8-11. PubMed ID: 15188648
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Epidemiologic study of measles, rubella and mumps with regard to the possibility of their control by immunization].
    Rodríguez Borrego MJ; García León J; Bolumar F; Nájera E
    Rev Sanid Hig Publica (Madr); 1985; 59(1-2):117-25. PubMed ID: 4059834
    [No Abstract]   [Full Text] [Related]  

  • 57. Live attenuated measles and mumps viral strain-containing vaccines and hearing loss: Vaccine Adverse Event Reporting System (VAERS), United States, 1990--2003.
    Asatryan A; Pool V; Chen RT; Kohl KS; Davis RL; Iskander JK;
    Vaccine; 2008 Feb; 26(9):1166-72. PubMed ID: 18255204
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Immune responses to measles and mumps vaccination of infants at 6, 9, and 12 months.
    Gans H; Yasukawa L; Rinki M; DeHovitz R; Forghani B; Beeler J; Audet S; Maldonado Y; Arvin AM
    J Infect Dis; 2001 Oct; 184(7):817-26. PubMed ID: 11528592
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Topics in clinical medicine. New vaccines against viral diseases: mumps, rubella, and measles.
    Seto DS; Carver DH
    Johns Hopkins Med J; 1969 Apr; 124(4):231-7. PubMed ID: 5774148
    [No Abstract]   [Full Text] [Related]  

  • 60. Evaluation of live trivalent vaccine of measles AIK-C strain, mumps Hoshino strain and rubella Takahashi strain, by virus-specific interferon-gamma production and antibody response.
    Nakayama T; Urano T; Osano M; Nakagawa M; Maehara N; Sasaki K; Yamamura AM; Makino S
    Microbiol Immunol; 1990; 34(6):497-508. PubMed ID: 2120551
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.